(Q37535680)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Nádia Emi Aikawa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Jozélio Freire de Carvalho

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Clovis Artur Almeida Silva

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

Clinical Reviews in Allergy & Immunology

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

82-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12016-009-8140-3

1 February 2020

exact match

0 references

cites work

Immunogenicity, efficacy and adverse events of adalimumab in RA patients

1 reference

12 December 2020

Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

12 December 2020

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

12 December 2020

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

12 December 2020

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

1 reference

12 December 2020

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

1 reference

12 December 2020

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

1 reference

12 December 2020

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

12 December 2020

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease

1 reference

12 December 2020

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

The biology of TNF blockade

1 reference

12 December 2020

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

12 December 2020

Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

1 reference

12 December 2020

Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis

1 reference

12 December 2020

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

1 reference

12 December 2020

Biological and clinical effects of anti-TNFalpha treatment

1 reference

12 December 2020

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

12 December 2020

Duration of remission of biologic agents for chronic plaque psoriasis.

1 reference

12 December 2020

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

1 reference

12 December 2020

Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up

1 reference

12 December 2020

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

1 reference

12 December 2020

Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab

1 reference

12 December 2020

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis

1 reference

12 December 2020

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

12 December 2020

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies

1 reference

12 December 2020

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

12 December 2020

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

12 December 2020

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

12 December 2020

Rheumatoid arthritis and tumor necrosis factor alpha

1 reference

12 December 2020

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

12 December 2020

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study

1 reference

12 December 2020

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

12 December 2020

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

12 December 2020